Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Randomized, double-blinded, controlled trial of the effects of coenzyme Q10 supplementation on plasma coenzyme Q10 concentration in dogs with myxomatous mitral valve disease
ID
Druzhaeva, Natalia
(
Author
),
ID
Domanjko-Petrič, Aleksandra
(
Author
),
ID
Tavčar-Kalcher, Gabrijela
(
Author
),
ID
Babič, Janja
(
Author
),
ID
Nemec Svete, Alenka
(
Author
)
DOCX - Presentation file,
Download
(70,87 KB)
MD5: 1B990652128DEC72D723FAF05497B941
URL - Source URL, Visit
https://avmajournals.avma.org/doi/10.2460/ajvr.82.4.280
Description: Dostopno z geslom
Image galllery
Abstract
OBJECTIVE To determine the dose of coenzyme Q10 (CoQ10) needed to achieve at least a 3-fold increase in plasma CoQ10 concentration in dogs with myxomatous mitral valve disease (MMVD) and congestive heart failure (CHF). ANIMALS 18 dogs with CHF due to MMVD and 12 healthy dogs. PROCEDURES In a randomized, double-blinded, controlled trial, dogs with MMVD were given 50 or 100 mg of water-soluble CoQ10 (ubiquinone; total daily dose, 100 mg [n = 5] or 200 mg [6]) or a placebo (7), PO, twice a day for 2 weeks in addition to regular cardiac treatment. Plasma CoQ10 concentration was measured in dogs with MMVD before (baseline) and at various time points after supplementation began and in healthy dogs once. Concentrations were compared among and within groups. RESULTS No significant difference in median baseline plasma CoQ10 concentration was detected between healthy dogs and dogs with MMVD. Fold increases in plasma CoQ10 concentrations ranged from 1.7 to 4.7 and 3.2 to 6.8 for in- dividual dogs in the 100-mg and 200-mg groups, respectively. The change in plasma CoQ10 concentration after supplementation began was significantly higher than in the placebo group at 4 hours and 1 and 2 weeks for dogs in the 200-mg group and at 1 and 2 weeks for dogs in the 100-mg group. CONCLUSIONS AND CLINICAL RELEVANCE A daily CoQ10 dose of 200 mg was sufficient to achieve at least a 3-fold increase in plasma CoQ10 concentration and may be used in CoQ10 supple- mentation studies involving dogs with CHF due to MMVD.
Language:
English
Keywords:
congestive heart failure
,
coenzyme Q10
,
myxomatous mitral valve disease
,
dogs
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
VF - Veterinary Faculty
Publication status:
Published
Publication version:
Author Accepted Manuscript
Article acceptance date:
17.08.2020
Year:
2021
Number of pages:
Str. 280-285
Numbering:
Vol. 82, no. 4
PID:
20.500.12556/RUL-132360
UDC:
636.09:616
ISSN on article:
0002-9645
DOI:
10.2460/ajvr.82.4.280
COBISS.SI-ID:
57671939
Publication date in RUL:
22.10.2021
Views:
815
Downloads:
146
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
American journal of veterinary research
Shortened title:
Am. j. vet. res.
Publisher:
American Veterinary Medical Association.
ISSN:
0002-9645
COBISS.SI-ID:
5084423
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:
15.04.2021
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P4-0053
Name:
Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back